AI‑driven biotech Earendil Labs signed an exclusive license and manufacturing pact with WuXi XDC to use the WuXiTecan‑2 payload‑linker platform for developing next‑generation antibody‑drug conjugates (ADCs). The agreement positions WuXi XDC to earn up to $885 million in upfront and milestone payments plus tiered royalties, and includes CRDMO support for ADC component manufacturing. Earendil said the WuXiTecan‑2 linker‑payload technology will accelerate its bispecific and multispecific ADC programs, including preclinical CEACAM5/CDH17 and TROP2/PDL1 constructs. The deal couples Earendil’s machine‑learning discovery capabilities with WuXi XDC’s conjugation and manufacturing infrastructure, aiming to speed ADC development and de‑risk conjugation chemistry at scale. Industry observers will monitor preclinical-to‑clinic translation timelines and how the parties allocate subsequent CMC and clinical milestones for candidate selection.